Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations
Top Cited Papers
Open Access
- 10 June 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (23), 2185-2193
- https://doi.org/10.1056/nejmoa0907328
Abstract
The use of valproic acid in the first trimester of pregnancy is associated with an increased risk of spina bifida, but data on the risks of other congenital malformations are limited.Keywords
This publication has 25 references indexed in Scilit:
- Management issues for women with epilepsy—Focus on pregnancy (an evidence‐based review): II. Teratogenesis and perinatal outcomesEpilepsia, 2009
- Teratogenesis of sodium valproateCurrent Opinion in Neurology, 2007
- Neuroteratogens in man: An overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancyReproductive Toxicology, 2006
- Valproic Acid in EpilepsyDrug Safety, 2006
- Prevention of stroke with ticlopidineNeurology, 1992
- Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsyEuropean Journal of Pharmacology, 1984
- MATERNAL VALPROIC ACID AND CONGENITAL NEURAL TUBE DEFECTSThe Lancet, 1982
- Possible teratogenicity of valproic acidThe Journal of Pediatrics, 1981
- VALPROIC ACID DURING PREGNANCYThe Lancet, 1980
- Sodium ValproateDrugs, 1977